Author Archives: admin

The Muscular Dystrophy Association announced today that it has awarded $1,549,725 to ReveraGen BioPharma, a Rockville, Md., biotechnology company, to develop and test a dissociative glucocorticoid as a potential treatment for Duchenne muscular dystroph…

MDA has awarded $1.5 million to ReveraGen BioPharma to develop a drug with the benefits of prednisone, but without the side effects, for Duchenne MD.

Longtime MDA research grantee Jerry Mendell discusses his group’s development of a feasible strategy for screening newborn babies for Duchenne MD.

News about the C9ORF72 gene, National ALS Registry and Cytokinetics’ experimental drug was reported at the 2012 American Academy of Neurology meeting.

Findings on the immune response to dystrophin in Duchenne and Becker MD, treatment of cardiomyopathy in DMD, and eteplirsen in DMD were presented.

Top researchers are discussing notable developments in neuroscience, including research in many neuromuscular diseases, at the annual American Academy of Neurology meeting April 21-28.

Repligen Corp., in Waltham, Mass., announced today that its experimental drug RG3039, designed to treat spinal muscular atrophy (SMA), was safe and well-tolerated in a phase 1 clinical trial.

In a phase 1 trial in healthy volunteers, Repligen’s experimental therapy for spinal muscular atrophy was safe and well tolerated, with hints of efficacy.

The Muscular Dystrophy Association announced today that SMT C1100, an experimental drug for Duchenne muscular dystrophy (DMD), has received approval from regulatory agencies in the United Kingdom to move from laboratory to human testing, starting with …

The experimental drug SMT C1100 is designed to increase utrophin production as a treatment for Duchenne MD.